Loading clinical trials...
Loading clinical trials...
A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Incyte Corporation
NCT05398809 · Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
NCT07029711 · Severe Alopecia Areata
NCT06826196 · Alopecia Areata (AA)
NCT05866562 · Alopecia Areata
NCT07136467 · Non-Segmental Vitiligo (NSV), Alopecia Areata, and more
Birmingham, Alabama
Hot Springs, Arkansas
New Haven, Connecticut
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions